The U.S. Food and Drug Administration (FDA) has approved labeling for Gardasil 9, an HPV vaccine, stating that it prevents oropharyngeal and other head and neck cancers caused by the virus.
The FDA is requesting that Gardasil's maker, Merck Sharp & Dohme, continue to study this particular clinical benefit; if postmarketing studies do not confirm the use of Gardasil for preventing these cancers, its clearance may be withdrawn or modified, the FDA said.
